Skip to main content

Table 2 HLA-G alleles, low-resolution groups and genotypes as related to outcomes of the genital and oral HPV infections during the six-year follow-up

From: HLA-G polymorphism impacts the outcome of oral HPV infections in women

 

Genital HPV infection outcomes1

Oral HPV infection outcomes1

HLA-G

Always negative

(n = 106)

Incidence

(n = 200)

Clearance

(n = 57)

Persistence

(n = 143)

Always negative

(n = 205)

Incidence

(n = 101)

Clearance

(n = 27)

Persistence

(n = 74)

Alleles

OR (95% CI)

OR (95% CI)

 *01:01:01

0.99 (0.45–2.19)

0.72 (0.37–1.40)

1.14 (0.61–2.12)

0.81 (0.44–1.50)

1.14 (0.62–2.10)

1.14 (0.59–2.21)

1.92 (0.86–4.29)

0.68 (0.34–1.32)

 *01:01:02

1.06 (0.59–1.92)

1.08 (0.67–1.75)

0.88 (0.55–1.40)

1.06 (0.67–1.67)

1.20 (0.76–1.90)

0.87 (0.53–1.42)

0.50 (0.29–0.79)

0.96 (0.56–1.65)

 *01:01:03

1.13 (0.44–2.91)

1.26 (0.56–2.87)

1.18 (0.54–2.64)

1.34 (0.63–2.85)

0.55 (0.25–1.21)

1.90 (0.89–4.07)

1.07 (0.46–2.51)

1.16 (0.49–2.72)

 *01:03:01

1.12 (0.23–5.42)

0.79 (0.22–2.86)

1.14 (0.32–4.13)

2.75 (0.70–10.82)

4.22 (0.88–20.22)

0.50 (0.10–2.39)

NC

0.34 (0.04–2.72)

 *01:04:01

0.98 (0.47–2.03)

0.78 (0.44–1.38)

1.08 (0.61–1.91)

0.81 (0.46–1.43)

1.74 (0.98–3.09)

0.54 (0.28–1.04)

0.66 (0.33–1.33)

0.92 (0.47–1.78)

 *01:06

0.44 (0.05–3.48)

2.45 (0.52–11.55)

1.34 (0.38–4.68)

0.64 (0.18–2.24)

0.57 (0.16–1.98)

1.17 (0.33–4.08)

1.10 (0.28–4.25)

1.84 (0.52–6.46)

Groups2

 G01:01

0.89 (0.10–8.16)

1.26 (0.21–7.68)

0.32 (0.04–2.94)

0.58 (0.95–3.52)

1.49 (0.25–9.05)

0.74 (0.12–4.47)

1.38 (0.15–12.49)

0.47 (0.77–2.88)

 G04:01

0.93 (0.45–1.92)

8.83 (0.47–1.47)

1.06 (0.60–1.87)

0.89 (0.51–1.55)

1.87 (1.06–3.30)

0.51 (0.27–0.98)

0.63 (0.32–1.26)

0.87 (0.45–1.69)

Genotypes

 010101:010101

1.25 (0.68–2.29)

1.19 (0.71–1.99)

1.01 (0.61–1.65)

0.87 (0.54–1.41)

0.54 (0.33–0.88)

1.49 (0.90–2.47)

1.18 (1–28-3.71)

1.44 (0.83–2.49)

 010101:010102

1.22 (0.64–2.29)

0.79 (0.47–1.33)

1.09 (0.66–1.84)

0.89 (0.54–1.47)

1.37 (0.83–2.28)

0.90 (0.52–1.55)

0.62 (0.33–1.51)

0.75 (0.41–1.38)

 010101:010103

0.51 (0.11–2.26)

2.99 (0.85–10.49)

1.09 (0.40–2.94)

1.61 (0.63–4.13)

0.57 (0.22–1.49)

1.91 (0.75–4.85)

1.05 (0.36–3.01)

1.49 (0.54–4.06)

 010101:010401

0.99 (0.43–2.27)

0.59 (0.31–1.12)

0.95 (0.50–1.82)

0.68 (0.35–1.31)

2.18 (1.12–4.26)

0.64 (0.31–1.32)

0.97 (0.46–2.03)

0.45 (0.18–1.11)

 010102:010102

0.49 (0.06–3.92)

1.25 (0.32–4.92)

0.60 (0.16–2.27)

1.14 (0.32–4.04)

0.67 (0.18–2.41)

0.87 (0.22–3.42)

1.26 (0.32–5.01)

1.36 (0.34–5.39)

 010102:010401

0.44 (0.05–3.48)

5.53 (0.70–43.77)

0.91 (0.27–3.04)

1.38 (0.41–4.63)

0.84 (0.25–2.81)

0.20 (0.02–1.54)

NC

4.01 (1.19–13.53)

  1. 1HPV outcomes definitions: incidence: baseline negative and acquired a HPV infection during follow-up, clearance: HPV positive and cleared the HPV (staying HPV negative to the end of the follow-up): persistence: recoded two or more consequence visit as HPV positive during the follow-up. 2Groups as low resolution for the following alleles G01:01: *010101, *010102, *010103, *010114 and G04:01: *01040 and *010404. Only those HLA-G alleles and genotypes that where > 3% prevalent among the women where included to the analyses. NC: Not Computable. The significant associations are bolded
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us